Morepen Laboratories Past Earnings Performance
Past criteria checks 5/6
Morepen Laboratories has been growing earnings at an average annual rate of 11.4%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 15.8% per year. Morepen Laboratories's return on equity is 9.7%, and it has net margins of 4.6%.
Key information
11.4%
Earnings growth rate
9.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 15.8% |
| Return on equity | 9.7% |
| Net Margin | 4.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Morepen Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16,422 | 761 | 2,127 | 0 |
| 30 Sep 23 | 15,433 | 531 | 1,958 | 0 |
| 30 Jun 23 | 15,238 | 477 | 2,884 | 0 |
| 31 Mar 23 | 14,220 | 387 | 1,654 | 0 |
| 31 Dec 22 | 14,270 | 428 | 1,800 | 0 |
| 30 Sep 22 | 14,765 | 553 | 1,843 | 0 |
| 30 Jun 22 | 14,721 | 768 | 2,604 | 0 |
| 31 Mar 22 | 15,558 | 1,017 | 1,724 | 0 |
| 31 Dec 21 | 14,743 | 1,161 | 1,809 | 0 |
| 30 Sep 21 | 13,854 | 1,184 | 1,589 | 0 |
| 30 Jun 21 | 13,295 | 1,082 | 2,092 | 0 |
| 31 Mar 21 | 11,980 | 971 | 1,407 | 0 |
| 31 Dec 20 | 11,136 | 814 | 1,345 | 0 |
| 30 Sep 20 | 10,380 | 684 | 1,279 | 0 |
| 30 Jun 20 | 9,183 | 453 | 1,678 | 0 |
| 31 Mar 20 | 8,584 | 336 | 1,143 | 0 |
| 31 Dec 19 | 8,731 | 331 | 1,161 | 0 |
| 30 Sep 19 | 8,530 | 312 | 1,118 | 0 |
| 30 Jun 19 | 8,117 | 340 | 1,474 | 0 |
| 31 Mar 19 | 7,714 | 288 | 995 | 0 |
| 31 Dec 18 | 7,258 | 252 | 980 | 0 |
| 30 Sep 18 | 6,672 | 267 | 879 | 0 |
| 30 Jun 18 | 6,436 | 308 | 841 | 0 |
| 31 Mar 18 | 6,101 | 296 | 807 | 0 |
| 31 Mar 17 | 5,991 | 236 | 739 | 0 |
| 31 Mar 16 | 4,861 | 128 | 616 | 0 |
| 31 Mar 15 | 4,014 | 21 | 517 | 0 |
| 31 Mar 14 | 3,670 | -28 | 807 | 4 |
Quality Earnings: 500288 has high quality earnings.
Growing Profit Margin: 500288's current net profit margins (4.6%) are higher than last year (3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 500288's earnings have grown by 11.4% per year over the past 5 years.
Accelerating Growth: 500288's earnings growth over the past year (78%) exceeds its 5-year average (11.4% per year).
Earnings vs Industry: 500288 earnings growth over the past year (78%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 500288's Return on Equity (9.7%) is considered low.